Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-based Aida Pharmaceuticals said that its anticancer drug has performed well in Phase II field testing with efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.
Subscribe to our email newsletter
The drug, Rh-Apo2L, is produced by genetic engineering and is designed as a highly targeted therapy with direct function on cancer cells.
Shanghai Qiaer, Aida’s research subsidiary, has reduced the key cancer targets to the three main diseases which Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date, pending successful trials.
Formal results will also be released after clinical tests are completed. After that, the company will apply for the approval of commencement of Phase III clinical trials from China’s State Food and Drug Administration (SFDA).
Assuming successful completion of all testing phases and approval of the drug by SFDA, Aida expects to have Rh-Apo2L on the market during the third quarter of 2008.